SCHEMBL4368285

SCHEMBL4368285

Nc1cccc(C2=C3C=NC=C[N+]3(N)C(c3ccc(Oc4ccccc4)cc3)=N2)c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 1/20 0.40
TNK2 Q07912 1/20 0.38
CHEK2 O96017 1/20 0.37
BTK Q06187 5/20 0.35
MAOA P21397 2/20 0.33
XDH P47989 1/20 0.33
MEN1 O00255 4/20 0.32
KMT2A Q03164 4/20 0.32
ALDH1A1 P00352 4/20 0.32
MAPT P10636 3/20 0.32
LMNA P02545 2/20 0.32
GPR55 Q9Y2T6 1/20 0.32
NPC1 O15118 2/20 0.32
RAB9A P51151 2/20 0.32
NLRP3 Q96P20 1/20 0.32
MITF O75030 1/20 0.32
GAA P10253 1/20 0.32
GFER P55789 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
NLRP1 Q9C000 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1131147 0.90 NPC1 (0.34) TNK2CHEK2BTKMAOAXDH
SCHEMBL4352081 0.89 MAOA (0.43) MAOBTNK2CHEK2BTKMAOA
SCHEMBL4360821 0.88 TNK2 (0.38) TNK2NPC1RAB9ASMN1; SMN2
SCHEMBL4366293 0.88 TNK2 (0.38) TNK2CHEK2XDH
SCHEMBL4364188 0.85 TNK2 (0.41) TNK2CHEK2
SCHEMBL4370412 0.85 AKR1C3 (0.42) TNK2CHEK2LMNAGAAKDM4E
SCHEMBL4352476 0.85 PARP10 (0.42) TNK2CHEK2BTK
SCHEMBL1129219 0.83 MAOB (0.36) MAOBCHEK2MEN1KMT2AALDH1A1
SCHEMBL4357979 0.83 LTA4H (0.42) TNK2BTKMEN1KMT2AALDH1A1
SCHEMBL4353437 0.83 MAPK14 (0.36) TNK2BTKXDHLMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8481733-B2 Substituted imidazopyr- and imidazotri-azines OSI Pharmaceuticals, LLC (US) 2013-07-09 US claimed
EP-2283020-B1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARM INC (US) 2012-10-31 EP claimed
US-8481733-B2 Substituted imidazopyr- and imidazotri-azines OSI Pharmaceuticals, LLC (US) 2013-07-09 US disclosed
EP-2283020-B1 SUBSTITUTED IMIDAZOPYR-AND IMIDAZOTRI-AZINES OSI PHARM INC (US) 2012-10-31 EP disclosed
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES OSI PHARMACEUTICALS, INC. (US) 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286768-A1 SUBSTITUTED IMIDAZOPYR- AND IMIDAZOTRI-AZINES ABL1, TPMT, CYP2C19 MAOB 1396/4885TNK2 2837/4885CHEK2 1900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.